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Summary
Objective: Secondary analyses of a previously conducted 1-year randomized controlled trial were performed to assess the application of
responder criteria in patients with knee osteoarthritis (OA) using different sets of responder criteria developed by the Osteoarthritis Research
Society International (OARSI) (Propositions A and B) for intra-articular drugs and Outcome Measures in Arthritis Clinical Trials
(OMERACT)eOARSI (Proposition D).
Methods: Two hundred ﬁfty-ﬁve patients with knee OA were randomized to ‘‘appropriate care with hylan G-F 20’’ (ACCH) or ‘‘appropriate care
without hylan G-F 20’’ (AC). A patient was deﬁned as a responder at month 12 based on change in Western Ontario and McMaster
Universities Osteoarthritis Index pain and function (0e100 normalized scale) and patient global assessment of OA in the study knee (at least
one-category improvement in very poor, poor, fair, good and very good). All propositions incorporate both minimum relative and absolute
changes.
Results: Results demonstrated that statistically signiﬁcant differences in responders between treatment groups, in favor of hylan G-F 20, were
detected for Proposition A (ACCHZ 53.5%, ACZ 25.2%), Proposition B (ACCHZ 56.7%, ACZ 32.3%) and Proposition D
(ACCHZ 66.9%, ACZ 42.5%). The highest effectiveness in both treatment groups was observed with Proposition D, whereas Proposition
A resulted in the lowest effectiveness in both treatment groups. The treatment group differences always exceeded the required 20% minimum
clinically important difference between groups established a priori, and were 28.3%, 24.4% and 24.4% for Propositions A, B and D,
respectively.
Conclusion: This analysis provides evidence for the capacity of OARSI and OMERACTeOARSI responder criteria to detect clinically
important statistically detectable differences between treatment groups.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Several different approaches to developing a deﬁnition for
a ‘‘responder’’ have been proposed for osteoarthritis (OA)
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Received 27 May 2004; revision accepted 22 October 2004.1clinical studies1e5. A conceptual approach to generally
categorizing various types of clinical difference has been
advanced by Beaton and colleagues6. A systematic
approach, based on the statistical analysis of data from
several previously completed placebo-controlled clinical
trials and multistakeholder consensus, has been conducted
by a working group of the Osteoarthritis Research Society
International (OARSI), and resulted in the formulation of
OARSI responder criteria A and B7. The original criteria
were different for different joints and classes of interven-
tions, Proposition A placing priority on high levels of pain
relief, while Proposition B permitted high relief in pain or04
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Arthritis Clinical Trials (OMERACT)eOARSI collaborative
exercise evaluated six scenarios and developed agreement
around Proposition D as a simpliﬁed set of responder
criteria applicable to different joints and types of interven-
tions8. In each of the aforementioned criteria sets, patients
are categorized as responders based on a combination of
absolute and percentage change on one or more OARSI
core set clinical measures of pain, physical function and
patient global assessment9,10. To assess the application of
responder criteria in OA patients, we have performed
secondary analyses of a previously published clinical
study1,11 to evaluate the capacity of responder criteria to
detect between-treatment differences in a randomized
clinical trial. In particular, we have compared the results of
analyses based on OARSI Proposition A, OARSI Proposi-
tion B and OMERACTeOARSI Proposition D to ascertain
whether the application of different criteria inﬂuences data
interpretation.
Methods
DESIGN
The analyses reported here were performed using the
data collected in a health outcomes trial evaluating
viscosupplementation with hylan G-F 20 when added to
an appropriate care treatment paradigm for patients with
knee OA. The detailed design of this trial and the primary
analyses of the data have been published elsewhere1.
Brieﬂy, the trial was a multicenter, randomized, controlled,
open-label study of 1-year duration, where patients were
randomized to either ‘‘appropriate care with hylan G-F 20’’
(ACCH) or ‘‘appropriate care without hylan G-F 20’’ (AC).
Appropriate care for knee OA was deﬁned by the Guide-
lines for the Medical Management of Osteoarthritis of the
Knee proposed by the American College of Rheumatology
(ACR)12. Patients in this study had symptomatic knee OA
(mild to moderate severity) and had received prior treatment
with analgesics. Appropriate care could include medications
such as analgesics, nonsteroidal anti-inﬂammatory drugs
(NSAIDs), corticosteroid injections, supportive measures
such as education and counseling, weight loss, joint rest,
application of heat or ice, and use of devices, physical
therapy, arthroscopy, and total joint replacement. Patients
randomized to the ACCH group could receive more than
one course of hylan G-F 20 treatment in the study knee
(knee most symptomatic or with the most predominant
musculoskeletal problem) if medically warranted, and could
receive bilateral treatment if their contralateral knee was
affected. Re-treatment was provided when persistent pain
recurred, with a minimum of 4 weeks between courses of
hylan G-F 20. The protocol did not allow hylan G-F 20
treatment for OA in joints other than the knee. Patients were
assessed by the clinical investigator at baseline and 12
months. Follow-up assessments were completed by tele-
phone at months 1, 2, 4, 6, 8, 10 and 12.
OUTCOME MEASURES
The Western Ontario and McMaster Universities (WO-
MAC) Osteoarthritis Index Likert 3.0 is a self-administered,
disease-speciﬁc health-related quality of life instrument that
asks the patients questions concerning the study knee. It
produces one aggregate total score (minimum: 0; maxi-
mum: 30) and scores for three subscales: pain, stiffness,and physical functioning. A greater score for each subscale
corresponds to a worsening condition. The pain subscale
includes ﬁve questions regarding the degree of pain experi-
enced with certain positions and activities (e.g., sitting or
lying), with a pain sub-score varying from 0 to 20. The
function subscale includes 17 questions regarding the
degree of difﬁculty experienced while completing activities
(e.g., descending stairs). The function sub-score varies
from 0 to 68. The stiffness subscale includes two questions
on severity of stiffness (i.e., after ﬁrst awakening, and later
in the day) with a sub-score varying from 0 to 8. For every
question in the WOMAC, patients rate their pain, stiffness,
and function using ﬁve ordinal responses: none, mild,
moderate, severe, and extreme.
Patient global assessments were also measured. The
questions that were completed by the patient were de-
veloped speciﬁcally for the original study, as no standard-
ized questions were available13. Patients were asked: ‘‘how
has the osteoarthritis in your study knee been during the
past 4 weeks?’’ This question was also asked for OA in all
affected joints, and for overall health. Patients answered
these questions using ﬁve ordinal responses: very good,
good, fair, poor and very poor. The WOMAC and the patient
global assessments were completed in the ofﬁce at
baseline and by telephone at follow-up assessments.
In the original study analysis1, the primary measure of
effectiveness was the mean change in the WOMAC pain
sub-score in the study knee from baseline. Secondary
effectiveness measures were the percentage of patients
improved at termination (compared to baseline) using
different combinations of the WOMAC subscales to deﬁne
an improved patient as follows: (1) at least 20% improve-
ment from baseline in the WOMAC pain score in the study
knee; and (2) at least 20% improvement from baseline in the
WOMAC pain score in the study knee and at least 20%
improvement from baseline in either function score or
stiffness score. The next section describes alternative
response criteria that were developed to provide a more
thorough characterization of who in general improves with
OA7,8.
OARSI AND OMERACT RESPONSE CRITERIA
Alternative effectiveness measures were examined in this
study. These measures were the percentage of patients
improved at termination (month 12) compared to baseline
using the three new responder criteria. Two of these criteria
were developed by the OARSI (Propositions A and B)
speciﬁcally to the treatment of knee OA with intra-articular
drugs7. The third was developed by the OMERACTeOAR-
SI8 task force and is a simpliﬁed set of criteria (Proposition D)
that is independent of drug and localization of OA (see Figs.
1e3). According to all propositions, a patient is deﬁned as
a responder, if either a ‘high’ response in pain (Proposition A)
or a high response in pain or function (Propositions B and D)
or a ‘moderate’ response in at least two domains (of pain,
function, global assessment) is achieved.
The following measures from our study were used to
generate inputs for determining fulﬁllment of the criteria, as
outlined in Figs. 1e3. Pain and function were measured by
the WOMAC pain and function subscales, at month 12 and
compared to baseline. The pain and function subscales of
the WOMAC were converted to a 0e100 normalized units
(NU) scale to correspond with the speciﬁc criteria outlined in
Propositions A, B and D. Patient global assessment of OA
in the study knee was measured using ﬁve ordinal
responses: very good, good, fair, poor, and very poor.
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AC=95/127=74.8
Yes
AC+H=47/127=37.0  No AC+H=80/127=63.0
AC=21/127=16.5 AC=106/127=83.5
Yes AC+H=21/127=16.5 No
AC=11/127=8.7
Non-responders
Moderate Improvement in at least 2 of the following
Pain > 35     and absolute change > 15 NU (AC+H=20/80=25.0    , AC=9/106=8.5 )
Function > 35     and absolute change > 10 NU (AC+H=22/80=27.5    , AC=14/106=13.2   )
Global assessment* > 30     and absolute change > 10 NU (AC+H=39/80=48.8    ,AC=47/106=44.3   )
Responder
Responder
High Improvement in pain > 40    and absolute change > 30 NU
All Responders AC+H=68/127=53.5
AC=32/127=25.2(Proposition A) 
*Moderate improvement in global assessment in these results was considered as at least a one-category, shift
(improvement) on a 5 point ordinal response scale (i.e. very poor, poor, fair, good and very good);
**Proposition A criteria for knee intra-articular specific drug;
NU = Normalized Units; 
AC+H = Appropriate Care + Hylan G-F 20; 
AC = Appropriate Care.
Fig. 1. Percentage of patients fulﬁlling speciﬁc criteria and overall response criteria for Proposition A**.The problem with such a scale is that calculating
a percentage change (e.g., at least 30%) or absolute
change (e.g., at least 10 NU on a 0e100 scale) in the spirit
of the propositions is not meaningful since the global scale
is discrete with only ﬁve categories. The proposition criteria
are suited more towards continuous scales, or scales that
are approximately continuous (e.g., WOMAC). Normalizing
the global assessment scale to 100 NU resulted in a
one-category improvement shift being equivalent to
25 NU, thus never allowing the proposition criteria to be
exactly fulﬁlled (i.e., absolute change of 10 NU required forall propositions). Thus, given the ordinal nature of the
patient global assessment scale, ‘moderate improvement’
was not deﬁned according to the proposition criteria; rather
it was operationally deﬁned as at least a one-category
improvement shift in response (e.g., good to very good).
Based on previous research14, a 20% difference between
treatment groups for the original measures of effectiveness
was established a priori by the steering committee and
investigators as the minimum clinically important difference.
This difference was applied to the new OARSI responder
criteria effectiveness measures.AC+H=55/127=43.3
AC=36/127=67.7
Yes
AC+H=50/127=39.4  No AC+H=77/127=60.6
AC=18/127=14.2 AC=109/127=85.8
Yes AC+H=22/127=17.3 No
AC=23/127=18.1
Non-responders
Moderate Improvement in at least 2 of the following
Pain > 20     and absolute change > 20 NU (AC+H=24/77=31.2    , AC=19/109=17.4   )
Function > 30     and absolute change > 10 NU (AC+H=26/77=33.8    , AC=21/109=19.3   )
Global assessment* > 30     and absolute change > 10 NU (AC+H=35/77=45.4    , AC=47/109=43.1    )
Responder
Responder
High Improvement in pain (> 50     and absolute change> 30 NU) OR function
(> 60     and absolute change> 20 NU)
All Responders
AC+H=72/127=56.7
AC=41/127=32.3(Proposition B) 
*Moderate improvement in global assessment in these results was considered as at least a one-directional category shift
(improvement) on a 5 point ordinal response scale (i.e. very poor, poor, fair, good and very good).
**Proposition B criteria for knee intra-articular specific drug.
NU = Normalized Units; 
AC+H = Appropriate Care + Hylan G-F 20; 
AC = Appropriate Care.
Fig. 2. Percentage of patients fulﬁlling speciﬁc criteria and overall response criteria for Proposition B**.
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AC=73/127=57.5
AC+H=85/127=66.9
AC=54/127=42.5
Yes
AC+H=58/127=45.7 No AC+H=69/127=54.3
AC=23/127=18.1 AC=104/127=81.9
 Yes AC+H=27/127=21.3 No
AC=31/127=24.4
Non-responders
Responder
Responder
Moderate Improvement in at least 2 of the following
Pain > 20     and absolute change > 10 NU (AC+H=29/69=42.0   , AC=29/104=27.9   )
Function > 20    and absolute change > 10 NU (AC+H=30/69=43.5    ,AC=28/104=26.9   )
Global assessment*> 20    and absolute change > 10 NU (AC+H=29/69=42.0    ,AC=44/104=42.3   )
High Improvement in pain or in function > 50    and absolute change > 20 NU
All Responders
(Proposition D) 
*Moderate improvement in global assessment in these results was considered as at least a one-category shift 
(improvement) on a 5-point ordinal response scale (i.e. very poor, poor, fair, good and very good).
NU = Normalized Units; 
AC+H = Appropriate Care + Hylan G-F 20; 
AC = Appropriate Care.
Fig. 3. Percentage of patients fulﬁlling speciﬁc criteria and overall response criteria for Proposition D.STATISTICAL METHODS
Data from the locked study database were analyzed using
SAS version 8.2. A logistic analysis was performed using
the new OARSI responder criteria deﬁned above (Proposi-
tions A, B, and D) with treatment group. A patient was
classiﬁed as a ‘‘responder’’ if the patient improved according
to the criteria outlined in the proposition from baseline to
month 12. The hypotheses to be tested were whether
ACCH was superior to AC when each of the new OARSI
responder criteria were applied, and if treatment group
differences were signiﬁcantly different from each other.
All analyses were adjusted for design variables (i.e.,
baseline value of the variable being analyzed, site, blocking
by site, body mass index, and baseline WOMAC total
score). The type 1 experiment-wise error rate was
controlled for by distributing alpha over all three compar-
isons (i.e., Propositions A, B, and D) using the Bonferroni
adjustment of alpha/3 (alpha for each comparisonZ 0.05/
3Z 0.0166). The original secondary effectiveness measure
(i.e., percentage of patients with at least 20% improvement
in the study knee at termination since baseline) was
analyzed using a logistic analysis that controlled for the
above-mentioned design variables. In this analysis, the type
1 experiment-wise error rate was not adjusted as there was
one secondary effectiveness measure. The results of the
original secondary analysis are provided for comparison to
the new OARSI responder criteria.
All patients were included in the intent-to-treat group for
all analyses as described earlier1. The hot deck method
was used to impute data for all effectiveness measures as
described earlier1.
Results
PATIENTS
In the trial, 128 patients were randomized to receive
appropriate care and 127 patients were randomized to
receive appropriate care with hylan G-F 20. A total of 24
patients dropped out of the study (21 in the AC group, 3 in
the ACCH group). One patient in the AC group did not havea baseline WOMAC questionnaire completed and was thus
not included in the analysis. Descriptive statistics comparing
demographics, baseline disease characteristics and base-
line outcome measures (i.e., WOMAC, global assessment)
are provided in Tables I and II. Overall, treatment groups
were similar with respect to demographics, disease charac-
teristics, and OA therapies used at baseline. However, 20%
of patients in the ACCH group and 33% of patients in the AC
group had grade IV OA, as subsequently determined by
central radiologic grading. In addition, 18% of patients in the
ACCH group and 30% of patients in the AC group had
a ‘very poor’ global assessment of OA in the study knee, at
baseline. Overall WOMAC scores for pain, stiffness and
function were similar between groups.
KNEE OA TREATMENT
All patients except one in the ACCH group had at least
one course of hylan G-F 20 in their study knee, and 53
(42%) had at least one course in their contralateral knee.
Forty-ﬁve patients (38%) in the ACCH group received
a second course of hylan G-F 20 in their study knee, and
three received a third course in their study knee. Twenty
patients (16%) in the ACCH group received a second
course in their contralateral knee. There were more patients
in the AC vs the ACCH group who reported corticosteroid
injection(s) in the study knee (89 vs 18) or the other knee
(35 vs 8) (both P! 0.0001). There were also more patients
in the AC group taking NSAIDs for any knee (101 vs 82)
(PZ 0.0062), and other medications (25 vs 13) (PZ
0.0216) (e.g., opioid analgesics, anti-inﬂammatories) for
any knee. There was no signiﬁcant difference between the
groups in the utilization of concomitant medications for
overall OA. Further details of knee OA treatment can be
found in the original study results1.
EFFECTIVENESS
The overall results for the original secondary effective-
ness measures and the new OARSI responder criteria
measures are provided in Table III. Figures 1e3 provide
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fulﬁlling the separate criteria within Propositions A, B, and
D. The results show that for all deﬁnitions of improvement,
the percentage of responders was greater in the ACCH
group vs the AC group. Also, the differences were
statistically signiﬁcant at the 0.0166 level (a/3Z 0.05/3)
for all deﬁnitions of patient improved (adjusted using the
Bonferroni correction) (Table III). The incremental difference
between treatment groups always exceeded the required
20% difference established a priori as the minimum
clinically important difference between groups. The magni-
tude of the treatment differences was similar across all
deﬁnitions of improvement, varying from 24.4% (Proposi-
tions B and D) to 28.3% (Proposition A, and ‘20%
improvement in pain’ criteria).
Table I
Demographics and disease status at baseline
Baseline measure ACCH, nZ 127 AC, nZ 128
Mean (SD) Mean (SD)
Age (years) 62.6 (9.4) 63.5 (10.5)
Body mass index (kg/m2) 32.1 (8.0) 32.9 (7.2)
Duration (years) of OA symptoms
Study knee 9.0 (9.5) 9.9 (9.7)
Other knee 7.4 (8.8) 8.3 (9.3)
n (%) n (%)
Sex: female 86 (68) 93 (73)
Previous therapy for OA of the knee(s)
Acetaminophen 100 (79) 109 (85)
NSAIDs 120 (94) 110 (86)
Prior surgery, study knee 40 (31) 39 (30)
Prior surgery, other knee 40 (31) 23 (18)
Radiology grading within 1 year (central grading*)
Not reported 0 (0) 1 (1)
Grade 0 4 (3) 4 (3)
Grade I 17 (13) 11 (9)
Grade II 32 (25) 33 (26)
Grade III 49 (39) 37 (29)
Grade IV 25 (20) 42 (33)
OA at baseline
Other knee affected 109 (86) 108 (84)
Other joints affected 95 (75) 87 (68)
*Radiology grading is based on central grading, which may have
differed from the site investigator’s determination for patient
eligibility.
Table II
WOMAC and patient global assessment at baseline
Baseline measure ACCH, nZ 127 AC, nZ 128
Mean (SD) Mean (SD)
WOMAC pain (0e20)* 11.4 (2.7) 11.9 (2.9)
WOMAC stiffness (0e8)* 5.1 (1.5) 5.1 (1.4)
WOMAC function (0e68)* 39.5 (9.3) 40.2 (9.3)
Patient global assessment of
OA in study knee
n (%) n (%)
Not reported 0 (0) 1 (1)
Very good 0 (0) 0 (0)
Good 2 (2) 1 (1)
Fair 44 (35) 31 (24)
Poor 58 (46) 57 (45)
Very poor 23 (18) 38 (30)
*The higher the score, the worse the problem. One patient in the
AC group did not have a WOMAC questionnaire completed at
baseline and was thus not included in the analysis.When comparing the new OARSI responder criteria, the
highest effectiveness in both treatment groups was ob-
served with Proposition D (66.9% vs 42.5%). Conversely,
Proposition A resulted in the lowest effectiveness in both
treatment groups (53.5% vs 25.2%). The difference
between treatment groups was similar for all propositions
(24.4%e28.3%) and was generally similar for the original
secondary measures of effectiveness.
Figures 1e3 describe the percentage of patients fulﬁlling
the speciﬁc criteria in each of Propositions A, B, and D. In the
ACCH group, two thirds of the patients fulﬁlled the criteria of
a ‘responder’ by having a ‘high’ improvement in pain
(Proposition A) or ‘high’ improvement in pain or function
(Propositions B and D). For example, for Proposition D,
45.7% of the ACCH group were considered responders
since they had a ‘high’ improvement response in pain or
function, where the overall percentage of responders was
66.9% (i.e., 45.7%/66.9%Z 68.3% or two thirds). For the
patients in the AC group, two thirds of patients (i.e., 16.5%/
25.2%Z 65.5% or two thirds) in Proposition A fulﬁlled the
criteria of responder by having a ‘high’ improvement in pain,
however, less than half of patients in Propositions B and D
fulﬁlled the criteria of responder by having had ‘high’
improvement in pain or function.
As the cut-off criteria for ‘moderate’ improvement
domains (pain, function, global assessment) become more
stringent moving from Propositions D to B to A, the
percentage of responders (i.e., by moderate improvement
only) in both treatment groups decreases (ACCH: 21.3%,
17.3%, 16.5%; AC: 24.4%, 18.1%, 8.7%, respectively). The
results also show that for Propositions A and B, the greatest
percentage of patients fulﬁlling ‘moderate’ improvement
criteria are numerically with the global assessment domain
(ACCH: 48.8%, 45.4%; AC: 44.3%, 43.1%, respectively).
For Proposition D, the percentage of patients fulﬁlling
‘moderate’ improvement criteria was similar across the
domains of pain and function and global assessment for
the ACCH group, but was higher for global assessment for
the AC group.
Discussion
Traditional methods of performing between-group com-
parisons of clinical trials data are frequently based on the
analysis of continuous variables. These provide an appre-
ciation of the magnitude and variation in group effects, but
do not permit reviewers an understanding of the degree of
improvement experienced by individual patients. In contrast,
responder criteria, while being reductionist from a group
standpoint, are capable of categorizing individual patients
according to whether they achieve levels of improvement at
or above pre-speciﬁed response thresholds. These thresh-
olds have been established a priori either to reﬂect
a clinically important difference at an individual level, or on
the basis of differentiating most efﬁciently between an active
treatment and a placebo control. In the case of the
effectiveness measures used in the original study1, they
were proposed during protocol development at a time when
there was no precedent to follow, but 20% was considered,
by the development group, to represent a minimum clinically
important difference. This difference was one that was of the
same order of magnitude as previously published ACR 20
criteria15 for rheumatoid arthritis clinical trials. The OARSI
responder criteria7 were developed during the execution of
the protocol, and the OMERACTeOARSI responder crite-
ria8 were developed following completion of the study. It is
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Summary of response criteria: improvement from baseline to month 12
Criteria Treatment group Difference
ACCH, nZ 127 AC*, nZ 127 [(ACCH) (AC)] P-value
n (%) n (%) (%)
Original effectiveness measures
R20% improvement in painy 87 (68.5) 51 (40.2) 28.3 0.0001
R20% improvement in pain and either
R20% improvement in function or stiffnessy
79 (62.2) 45 (35.4) 26.8 0.0001
New OARSI response criteria
Proposition A (OARSI) 68 (53.5) 32 (25.2) 28.3 !0.0001
Proposition B (OARSI) 72 (56.7) 41 (32.3) 24.4 0.0002
Proposition D (OMERACTeOARSI) 85 (66.9) 54 (42.5) 24.4 0.0002
*One patient in the AC group did not have a WOMAC questionnaire completed at baseline and was thus not included in the analysis.
ySecondary effectiveness measures from main study.of interest therefore that these different approaches,
separated in time and concept, all yield comparable,
statistically detectable between-group differences, in favor
of ACCH, of 24.4%e28.3%.
It is worthy of note that different criteria, while yielding
very similar between-group differences (24.4%e28.3%)
(Table III), specify quite different percentages of both
ACCH (53.5%e68.5%) and AC alone (25.2%e42.5%)
patients as responders. For this reason, the criteria should
not be considered interchangeable, but rather complemen-
tary. The OARSIeOMERACT Proposition D, and the
WOMAC 20% improvement in pain response criteria, yield
very similar by-group percentage response rates and
similar between-group differences in this study. The
generalizability of this observation will require further study.
This similarity in results may be explained by the re-
quirement for those not fulﬁlling the primary requirement in
Proposition D, of alternatively experiencing an improvement
of 20% or greater in pain, function or global assessment. In
contrast, Propositions A and B require secondary improve-
ments of 30% (Proposition A) or 20% or greater, re-
spectively (Proposition B). Thus, the similarity between the
lowest threshold for pain on Proposition D and WOMAC
20% improvement in pain criteria are similar in percentage
terms, and may explain the comparable yields. However,
since there is no absolute change required for the WOMAC
20% improvement in pain criteria, whereas in Proposition D
an improvement of at least 10 NU is required, the two
approaches may yield different results with differing re-
sponse distributions, and may therefore differ from study to
study.
Furthermore, the patients in this study had mean baseline
scores in or about the midpoint on all three WOMAC
subscales. Whether these observations can be generalized
to patients with either more or less severe symptoms will
require further study. The pattern of improvement in patient
global assessment is different from that in pain and function.
For Propositions A and B, the percentage of responders for
moderate improvement in global assessment is greater
than the percentage of responders for moderate improve-
ment in pain or function (Figs. 1, 2). Hoeksma et al.16 have
observed that fewer patients with hip OA were classiﬁed as
improved with OARSI response criteria as compared to
patient’s global assessment. This suggested to the inves-
tigators that the OARSI response criteria provided a ‘‘more
objective reﬂection of the actual clinical status of patients
with OA of the hip’’. Taken collectively, these observations
suggest that the wording and scaling of the patient globalassessment question might require further consideration for
application in studies employing responder analyses.
The results of this analysis provide evidence for the
capacity of responder criteria to detect clinically important
statistically detectable differences between two active
treatment groups in a randomized clinical trial. These
observations support those of other investigators who have
reported their experience on the responsiveness of the
OARSI responder criteria17e19. In particular, this approach
allows reviewers and consumers to discern how many
patients experienced a clinically important reduction in the
severity of their symptoms. Given that the analytic strategy
is individualized, this approach may have important
implications for monitoring patients in routine clinical care
and facilitating evidence-based therapeutic decision mak-
ing, and shared goal setting, in various health care
environments.
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